Skip to main content
. Author manuscript; available in PMC: 2008 Nov 7.
Published in final edited form as: Vaccine. 2007 Sep 4;25(45):7824–7831. doi: 10.1016/j.vaccine.2007.08.036

Figure 3. CTL assay with luciferase-expressing tumor cells using T cells from the various vaccinated mice groups.

Figure 3

Splenocytes from immunized mice were harvested as previously described in Figure 2 and stimulated with E6 peptide (aa49-57) for 120hr, then added in several effector:target ratios to TC-1/Luciferase target cells previously plated in 96-well plates. Following 8hr incubation, media was drawn from the wells, briefly centrifuged, and quantitatively assayed for luciferase activity using the Steady-Glo reagent (Promega, Madison, WI). Visualization and quantitation was performed using Xenogen IVIS system and Living Image software package (Xenogen Corp., Alameda, CA) as a readout for target cell lysis (*p<0.001).